Comparing long-term weight loss and complications in endoscopic sleeve gastroplasty and laparoscopic sleeve gastrectomy: a systematic review and meta-analysis.

Surg EndoscSep 10, 2026 (epub)
Clinical ResearchGastroenterologyGeneral SurgeryOpen access

Gabriel LaPlante, Sunpreet Cheema, Brianna Brand et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared long-term outcomes of endoscopic sleeve gastroplasty (ESG) and laparoscopic sleeve gastrectomy (LSG) in 7442 patients. ESG was associated with lower total body weight loss at 6, 12, and 24 months, but also a significantly lower risk of overall adverse events and de novo gastro-esophageal reflux disease (GERD).

Key findings

  • ESG resulted in lower total body weight loss at 6 months (-8.34%) compared to LSG.
  • At 12 months, ESG showed a mean difference in total body weight loss of -12.58%.
  • ESG had a reduced risk of overall adverse events (RR 0.54) compared to LSG.
  • The risk of de novo GERD was significantly lower in the ESG group (RR 0.33).

Why it matters

Understanding the comparative outcomes of ESG and LSG is crucial for clinicians in guiding patients towards appropriate bariatric options, especially for those concerned about surgical risks or pre-existing GERD.

Source

PubMed · PMID 42722912Free full text on PubMed Central

Published in Surg Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.